To add to my previous comment......The price tag m
Post# of 148188
(Total Views: 444)
Posted On: 08/15/2019 5:03:12 PM
To add to my previous comment......The price tag may have an influence on license deal though.....BP should use this to determine valuation for various indications.
I have always thought that if licensed out it will be priced higher as BP wants as much revenue as possible and likely already owns a large percentage of the other non-MDR2+ patient population. Lower price tag benefits CYDY more of going alone as they could establish a larger market share and likely steal some patients from competition. Word of mouth and referrals would only make mono more likely successful for off-label or once approved. JMO.
I have always thought that if licensed out it will be priced higher as BP wants as much revenue as possible and likely already owns a large percentage of the other non-MDR2+ patient population. Lower price tag benefits CYDY more of going alone as they could establish a larger market share and likely steal some patients from competition. Word of mouth and referrals would only make mono more likely successful for off-label or once approved. JMO.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Please do your own due diligence. All my posts and comments are not to be considered investment advice.
Scroll down for more posts ▼